Duodopa® treatment for advanced Parkinson's disease: A review of efficacy and safety

Parkinsonism and Related Disorders

Volumn 18, Issue 8, 2012, Pages 916-929

  Nyholm, Dag ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Clinically important difference; Duodopa ; Efficacy; Parkinson's disease; Safety

Indexed keywords

APOMORPHINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; ROTIGOTINE; TOLCAPONE;

AGITATION; AMINO ACID BLOOD LEVEL; ANXIETY; BEHAVIOR DISORDER; BRAIN DEPTH STIMULATION; CLINICAL EFFECTIVENESS; CONFUSION; CONSTIPATION; CYANOCOBALAMIN DEFICIENCY; DEPRESSION; DIARRHEA; DOPAMINE DYSREGULATION SYNDROME; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSKINESIA; DYSTONIA; FALLING; FATIGUE; HALLUCINATION; HOMOCYSTEINE BLOOD LEVEL; HUMAN; HYPERHIDROSIS; HYPERKINESIA; INSOMNIA; METABOLIC DISORDER; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SOMNOLENCE; SUICIDE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; WEIGHT REDUCTION;

ANIMALS; ANTIPARKINSON AGENTS; CARBIDOPA; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS; LEVODOPA; PARKINSON DISEASE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84865604071     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.06.022     Document Type: Review

References (69)

1. de Rijk M.C., Tzourio C., Breteler M.M., Dartigues J.F., Amaducci L., Lopez-Pousa S., et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON collaborative study. European community concerted action on the epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997, 62:10-15.
2. Fahn S., Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 2004, 1:139-154.
3. Eggert K., Schrader C., Hahn M., Stamelou M., Russmann A., Dengler R., et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008, 31:151-166.
4. Nyholm D., Lennernas H., Gomes-Trolin C., Aquilonius S.M. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin Neuropharmacol 2002, 25:89-96.
5. Gershanik O., Jenner P. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease. Eur J Neurol 2012, [Epub ahead of print].
6. Nyholm D., Nilsson Remahl A.I., Dizdar N., Constantinescu R., Holmberg B., Jansson R., et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005, 64:216-223.
7. van Laar T. Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management. CNS Drugs 2003, 17:475-489.
8. Nyholm D., Lennernas H. Irregular gastrointestinal drug absorption in Parkinson's disease. Expert Opin Drug Metab Toxicol 2008, 4:193-203.
9. Nilsson D., Hansson L.E., Johansson K., Nystrom C., Paalzow L., Aquilonius S.M. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand 1998, 97:175-183.
10. Clarke C.E., Worth P., Grosset D., Stewart D. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2009, 15:728-741.
11. Devos D. French Duodopa study group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009, 24:993-1000.
12. Garcia-Ruiz P.J., Del Val J., Fernandez I.M., Herranz A. What factors influence motor complications in Parkinson disease?: a 10-year prospective study. Clin Neuropharmacol 2012, 35:1-5.
13. Antonini A., Isaias I.U., Canesi M., Zibetti M., Mancini F., Manfredi L., et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007, 22:1145-1149.
14. Food and Drug Administration List of orphan product designations for January 2000 2000, Food and Drug Administration.
15. European Medicines Agency Public summary of opinion on orphan designation 2011, (updated 15 March 2011).
16. Australian Therapeutic Goods Administration Orphan drugs 2010.
17. Shulman L.M., Gruber-Baldini A.L., Anderson K.E., Fishman P.S., Reich S.G., Weiner W.J. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol 2010, 67:64-70.
18. Antonini A., Mancini F., Canesi M., Zangaglia R., Isaias I.U., Manfredi L., et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Dis 2008, 5:244-246.
19. Elia A.E., Dollenz C., Soliveri P., Albanese A. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation. Eur J Neurol 2012, 19:76-83.
20. Honig H., Antonini A., Martinez-Martin P., Forgacs I., Faye G.C., Fox T., et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009, 24:1468-1474.
21. Isacson D., Bingefors K., Kristiansen I.S., Nyholm D. Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurol Scand 2008, 118:379-386.
22. Karlsborg M., Korbo L., Regeur L., Glad A. Duodopa pump treatment in patients with advanced Parkinson's disease. Dan Med Bull 2010, 57:A4155.
23. Klostermann F., Jugel C., Marzinzik F. Benefit from jejunal levodopa in a patient with apomorphine pump. J Neurol 2011, 258:311-312.
24. Klostermann F., Jugel C., Marzinzik F. Jejunal levodopa infusion in long-term DBS patients with Parkinson's disease. Mov Disord 2011, 26:2298-2299.
25. Meiler B., Andrich J., Muller T. Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion. Mov Disord 2008, 23:145-146.
26. Meppelink A.M., Nyman R., van Laar T., Drent M., Prins T., Leenders K.L. Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease. Mov Disord 2011, 26:331-334.
27. Merola A., Zibetti M., Angrisano S., Rizzi L., Lanotte M., Lopiano L. Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease. Mov Disord 2011, 26:664-670.
28. Nilsson D., Nyholm D., Aquilonius S.M. Duodenal levodopa infusion in Parkinson's disease-long-term experience. Acta Neurol Scand 2001, 104:343-348.
29. Nyholm D., Askmark H., Gomes-Trolin C., Knutson T., Lennernas H., Nystrom C., et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003, 26:156-163.
30. Nyholm D., Johansson A., Lennernas H., Askmark H. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. Eur J Neurol 2011, 19:820-826.
31. Nyholm D., Johansson A., Aquilonius S.M., Hellquist E., Lennernas H., Askmark H. Complexity of motor response to different doses of duodenal levodopa infusion in Parkinson disease. Clin Neuropharmacol 2012, 35:6-14.
32. Puente V., De Fabregues O., Oliveras C., Ribera G., Pont-Sunyer C., Vivanco R., et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord 2010, 16:218-221.
33. Raudino F., Garavaglia P., Pianezzola C., Riboldazzi G., Leva S., Guidotti M., et al. Long-term experience with continuous duodenal levodopa-carbidopa infusion (Duodopa): report of six patients. Neurol Sci 2009, 30:85-86.
34. Sanchez-Castaneda C., Campdelacreu J., Miro J., Juncadella M., Jauma S., Calopa M. Cognitive improvement after duodenal levodopa infusion in cognitively impaired Parkinson's disease patients. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:250-251.
35. Santos-Garcia D., Sanjurjo L.F., Macias M., Llaneza M., Carpintero P., de la Fuente-Fernandez R. Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being. Acta Neurol Scand 2012, 125:187-191.
36. US Department of Health and Human Services Acute pain management: operative or medical procedures and trauma (AHCPR Publication No. 92-0023) 1993, The Agency for Health Care Policy and Research, Rockville, p. 107.
37. Miller I.N., Cronin-Golomb A. Gender differences in Parkinson's disease: clinical characteristics and cognition. Mov Disord 2010, 25:2695-2703.
38. Haaxma C.A., Bloem B.R., Borm G.F., Oyen W.J., Leenders K.L., Eshuis S., et al. Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007, 78:819-824.
39. Fahn S., Elton R. Members of the UPDRS development committee. UPDRS. Recent developments in Parkinson's disease 1987, 153-163. Macmillan Health Care Education, Florham park, 293-304. S. Fahn, C.D. Marsden, D.B. Calne, M. Goldstein (Eds.).
40. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008, 79:368-376.
41. Hauser R.A., Auinger P. Determination of minimal clinically important change in early and advanced Parkinson's disease. Mov Disord 2011, 26:813-818.
42. Schrag A., Sampaio C., Counsell N., Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord 2006, 21:1200-1207.
43. Peto V., Jenkinson C., Fitzpatrick R. Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire. Age Ageing 2001, 30:299-302.
44. Luo N., Tan L.C., Zhao Y., Lau P.N., Au W.L., Li S.C. Determination of the longitudinal validity and minimally important difference of the 8-item Parkinson's disease questionnaire (PDQ-8). Mov Disord 2009, 24:183-187.
45. Peto V., Jenkinson C., Fitzpatrick R., Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995, 4:241-248.
46. Jenkinson C., Fitzpatrick R., Peto V., Greenhall R., Hyman N. The Parkinson's disease questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997, 26:353-357.
47. Santos-Garcia D., Anon M.J., Fuster-Sanjurjo L., de la Fuente-Fernandez R. Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson's disease leads to improvement in caregivers' stress and burden. Eur J Neurol 2012, [Epub ahead of print].
48. Antonini A., Bondiolotti G., Natuzzi F., Bareggi S.R. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. Eur Neuropsychopharmacol 2010, 20:683-687.
49. Muller T., Jugel C., Ehret R., Ebersbach G., Bengel G., Muhlack S., et al. Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel. J Neural Transm 2011, 118:1329-1333.
50. Negreanu L.M., Popescu B.O., Babiuc R.D., Ene A., Andronescu D., Bajenaru O.A. Cutting the Gordian knot: the blockage of the jejunal tube, a rare complication of Duodopa infusion treatment. J Med Life 2010, 3:191-192.
51. Negreanu L., Popescu B.O., Babiuc R.D., Ene A., Bajenaru O.A., Smarandache G.C. Duodopa infusion treatment: a point of view from the gastroenterologist. J Gastrointestin Liver Dis 2011, 20:325-327.
52. Nyholm D., Jansson R., Willows T., Remahl I.N. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology 2005, 65:1506-1507.
53. Nyholm D., Lewander T., Johansson A., Lewitt P.A., Lundqvist C., Aquilonius S.M. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008, 31:63-73.
54. Nyman R., Lundgren D., Nyholm D. Soft tissue-anchored transcutaneous port attached to an intestinal tube for long-term gastroduodenal infusion of levodopa/carbidopa in Parkinson disease. J Vasc Interv Radiol 2009, 20:500-505.
55. Santos-Garcia D., Macias M., Llaneza M., Aneiros A. Suicide following duodenal levodopa infusion for Parkinson's disease. Mov Disord 2009, 24:2029-2030.
56. Santos-Garcia D., Macias M., Llaneza M., Grande M., de la Fuente-Fernandez R. Serum vitamin B(12) and folate levels in Parkinson's disease patients treated with duodenal levodopa infusion. Mov Disord 2011, 26:558-559.
57. Santos-Garcia D., de la Fuente-Fernandez R., Valldeoriola F., Palasi A., Carrillo F., Grande M., et al. Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert. J Neurol 2012, [Epub ahead of print].
58. Schrader C., Boselt S., Wedemeyer J., Dressler D., Weismuller T.J. Asparagus and jejunal-through-PEG: an unhappy encounter in intrajejunal levodopa infusion therapy. Parkinsonism Relat Disord 2011, 17:67-69.
59. Wolters E., Lees A.J., Volkmann J., van Laar T., Hovestadt A. Managing Parkinson's disease with continuous dopaminergic stimulation. CNS Spectr 2008, 13:1-14. quiz 5-6.
60. Busk K., Nyholm D. Long-term 24-h levodopa/carbidopa gel infusion in Parkinson's disease. Parkinsonism Relat Disord 2012, [Epub ahead of print].
61. Westin J., Dougherty M., Nyholm D., Groth T. A home environment test battery for status assessment in patients with advanced Parkinson's disease. Comput Methods Programs Biomed 2010, 98:27-35.
62. Westin J., Schiavella M., Memedi M., Nyholm D., Dougherty M., Antonini A. Validation of a home environment test battery for supporting assessments in advanced Parkinson's disease. Neurol Sci 2011, [Epub ahead of print].
63. Nyholm D., Klangemo K., Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol 2012.
64. Rajabally Y.A., Martey J. Neuropathy in Parkinson disease: prevalence and determinants. Neurology 2011, 77:1947-1950.
65. Toth C., Breithaupt K., Ge S., Duan Y., Terris J.M., Thiessen A., et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 2010, 68:28-36.
66. Klostermann F., Jugel C., Muller T., Marzinzik F. Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm 2012, 119:369-372.
67. Dellon A.L., Dellon E.S., Tassler P.L., Ellefson R.D., Hendrickson M. Experimental model of pyridoxine (B6) deficiency-induced neuropathy. Ann Plast Surg 2001, 47:153-160.
68. Saperstein D.S., Wolfe G.I., Gronseth G.S., Nations S.P., Herbelin L.L., Bryan W.W., et al. Challenges in the identification of cobalamin-deficiency polyneuropathy. Arch Neurol 2003, 60:1296-1301.
69. Urban P.P., Wellach I., Faiss S., Layer P., Rosenkranz T., Knop K., et al. Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord 2010, 25:1748-1752.